A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Cancer
Hlavní autoři: Wu, Di, Nie, Jun, Hu, Weiheng, Dai, Ling, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2020
Témata:
Cancer Therapy and Prevention
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689882/
https://ncbi.nlm.nih.gov/pubmed/32557583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33161
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky